Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170013 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL30189955 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL691842 | 0.94 | ALDH1A1 (0.92) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL13125941 | 0.92 | ALDH1A1 (0.89) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL13125914 | 0.86 | ALDH1A1 (0.78) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL6862670 | 0.76 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL2035154 | 0.74 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL167247 | 0.74 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| Bromide SCHEMBL8070341 | 0.74 | ALDH1A1 (0.56) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA | |
| SCHEMBL2691499 | 0.73 | ALDH1A1 (0.59) | ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-1878731-B1 | Process for producing pramipexole | HELM AG (DE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1878731-A1 | Process for producing pramipexole | Helm AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | ACHE 4626/4885ALDH1A1 4152/4885MAPK1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.